1-甲基哌嗪-2-酮三氟乙酸酯 | 194350-88-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-甲基哌嗪-2-酮三氟乙酸酯
• 英文名称: 1-Methylpiperazin-2-one trifluoroacetate
• 英文别名: 1-methylpiperazin-2-one;2,2,2-trifluoroacetic acid
• CAS: 194350-88-4
• 化学式: C7H11F3N2O3
• 分子量: 228.17
• InChiKey: IGKQGGBDLSXHJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.32
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为产物：
  描述：

  三氟乙酸 、 4-甲基-3-氧代-哌嗪-1-羧酸叔丁酯 以 二氯甲烷 为溶剂， 反应 1.5h， 以to thereby give the title compound (0.485 g, quantitative amount)的产率得到1-甲基哌嗪-2-酮三氟乙酸酯
  参考文献：
  名称：

  Five-membered heterocyclic derivative

  摘要：

  本发明涉及一种由公式（I）表示的化合物：该化合物的盐，或该化合物或盐的溶剂化物；含有任何该化合物、盐和溶剂化物的药物；含有任何该化合物、盐和溶剂化物的缺血性疾病的预防和/或治疗剂；以及含有任何该化合物、盐和溶剂化物的血小板凝集抑制剂。本发明的化合物在不抑制COX-1或COX-2的情况下作为强效的血小板凝集抑制剂非常有用。

  公开号：

  US20060189591A1

文献信息

• Aminobenzoxazoles as therapeutic agents
  申请人：Wishart Neil

  公开号：US20060025383A1

  公开（公告）日：2006-02-02

  A compound of Formula (I), wherein the substituents are as defined herein, which are useful as kinase inhibitors.

  其中取代基如本文所述的公式(I)的化合物，用作激酶抑制剂。
• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• [EN] 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY<br/>[FR] DÉRIVÉS DE 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE UTILISÉS COMME INHIBITEURS DE L'ACTIVITÉ DE LA TYROSINE KINASE MAMMIFÈRE ROR1
  申请人：KANCERA AB

  公开号：WO2018011138A1

  公开（公告）日：2018-01-18

  Compound of formula (I´) or (I´´) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

  化合物的化学式为(I´)或(I´´)，或其药学上可接受的盐。该化合物是哺乳动物激酶酶活性的抑制剂，包括ROR1酪氨酸激酶活性，并可用于治疗与此类活性相关的疾病。
• Piperidine derivatives and their use as antagonists of tachykinins
  申请人：Alvaro Giuseppe

  公开号：US20050096313A1

  公开（公告）日：2005-05-05

  The present invention relates to piperidine derivatives of formula (I): wherein R represents halogen or C 1-4 alkyl; R 1 represents hydrogen or C 1-4 alkyl; R 2 represents hydrogen, C 1-4 alkyl; R 3 represents hydrogen, C 1-4 alkyl; R 4 represents trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy or halogen; R 5 represents hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, C(O)R 6 or S(O) 2 R 6 ; R 6 represents C 1-4 alkyl or C 3-7 cycloalkyl; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; p is an integer from 1 to 2; X and Y are independently C(O) or CH 2 ; provided that i) X and Y are not both C(O) and ii) when X and Y are both CH 2 and p is 1, R 5 is not hydrogen, C 1-4 alkyl or C(O)R 6 ; and pharmaceutically acceptable salts and solvates thereof, the process for their preparation and their use in the treatment of conditions mediated by tachykinins.

  本发明涉及式（I）的哌啶衍生物：其中R代表卤素或C1-4烷基；R1代表氢或C1-4烷基；R2代表氢，C1-4烷基；R3代表氢，C1-4烷基；R4代表三氟甲基，C1-4烷基，C1-4烷氧基，三氟甲氧基或卤素；R5代表氢，C1-4烷基，C3-7环烷基，C（O）R6或S（O）2R6；R6代表C1-4烷基或C3-7环烷基；m为零或1至3的整数；n为1至3的整数；p为1至2的整数；X和Y分别为C（O）或CH2；前提是i）X和Y不都是C（O）；以及ii）当X和Y都是CH2且p为1时，R5不是氢，C1-4烷基或C（O）R6；以及其药学上可接受的盐和溶剂合物，其制备过程及其在治疗缓解性肽介导的疾病中的用途。
• Pyrazole derivative
  申请人：Kanaya Naoaki

  公开号：US20060128685A1

  公开（公告）日：2006-06-15

  The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. The present invention provides compounds represented by formula (I) or formula (II), salts of the compounds, and solvates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates.

  本发明旨在提供一种强的血小板聚集抑制剂，其不抑制COX-1或COX-2。本发明提供了由式（I）或式（II）表示的化合物，化合物的盐以及化合物或盐的溶剂。还提供了包含任何一种化合物、盐或溶剂的药物以及预防和/或治疗缺血性疾病的制剂，其中包含任何一种化合物、盐或溶剂。